首页 > 最新文献

ecancermedicalscience最新文献

英文 中文
Tyrosine crystal deposition in pleomorphic adenoma: a rare presentation in a male smoker with long-term follow-up. 多形性腺瘤中的酪氨酸晶体沉积:一名男性吸烟者的罕见病例及长期随访。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1776
Sandhya Tamgadge, Gokul Venkateshwar, Treville Pereira, Avinash Tamgadge, Simran Pethani

This case report presents the diagnosis and management of a pleomorphic adenoma in a 55-year-old male smoker with a habit of smoking tobacco for 6 years. The patient presented with a chief complaint of swelling in the posterior palatal region. Clinical examination revealed a well-circumscribed, non-tender, firm swelling in the palatal region. An incisional biopsy followed by surgical excision was performed, and histopathological evaluation confirmed the diagnosis of pleomorphic adenoma. Tyrosine crystals were observed within the tumour stroma, providing additional diagnostic insight. A 10-year post-operative follow-up revealed no recurrence of the lesion.

本病例报告介绍了一名 55 岁男性吸烟者的多形性腺瘤的诊断和治疗,该吸烟者有吸烟 6 年的习惯。患者主诉腭后部肿胀。临床检查发现,腭部肿物呈环状,无触痛,质地坚硬。切口活检后进行了手术切除,组织病理学评估证实了多形性腺瘤的诊断。在肿瘤基质中发现了酪氨酸晶体,为诊断提供了更多依据。术后 10 年的随访显示病灶没有复发。
{"title":"Tyrosine crystal deposition in pleomorphic adenoma: a rare presentation in a male smoker with long-term follow-up.","authors":"Sandhya Tamgadge, Gokul Venkateshwar, Treville Pereira, Avinash Tamgadge, Simran Pethani","doi":"10.3332/ecancer.2024.1776","DOIUrl":"10.3332/ecancer.2024.1776","url":null,"abstract":"<p><p>This case report presents the diagnosis and management of a pleomorphic adenoma in a 55-year-old male smoker with a habit of smoking tobacco for 6 years. The patient presented with a chief complaint of swelling in the posterior palatal region. Clinical examination revealed a well-circumscribed, non-tender, firm swelling in the palatal region. An incisional biopsy followed by surgical excision was performed, and histopathological evaluation confirmed the diagnosis of pleomorphic adenoma. Tyrosine crystals were observed within the tumour stroma, providing additional diagnostic insight. A 10-year post-operative follow-up revealed no recurrence of the lesion.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1776"},"PeriodicalIF":1.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A physiotherapists perspective of a geriatric clinic in a tertiary oncology centre. 物理治疗师对三级肿瘤中心老年病诊所的看法。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-20 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1774
Ankita Chitre, Akhil Kapoor, Bipinesh Sansar, Anuj Gupta, Praveen Lakshmanamurthy, Somnath Dey, Kunal Vinayak, Ajit Sahoo, Navneet Kaur, Sumaiya Azeem, Dipti Kadu, Akash Anand Shrivastav
<p><strong>Aims and objectives: </strong>To analyse various domains amongst the geriatric population such as age, gender, body mass index (BMI), comorbidities, type of cancer and use of assistive devices, and find a correlation between the outcome measures such as short physical performance battery (SPPB) and performance-oriented mobility assessment (POMA).</p><p><strong>Methodology: </strong>Patients above 60 years were screened and further referred to the physiotherapy department. A brief history was recorded to retrieve the demographic data such as name, age, gender, height, weight, BMI, hand dominance, diagnosis, previous investigations are done, comorbidities if any present, use of assistive devices if required and in case any previous oncological treatment has been delivered. Various outcome measures were administered such as POMA, SPPB, 6 minutes walk test (6 MWT) and numerical rating for fatigue. The interpretations were noted on a case report sheet and the appropriate interventions for the deficits were delivered to the patient. Also, the patients were asked to carry on the necessary investigation (if required) and get back to the physiotherapy OPD. No follow-up is required by the patients as this was a retrospective single-endpoint study.</p><p><strong>Results and analysis: </strong>The descriptive analysis was done by using R software (version 4.2.3). The main objective was to analyse the variables descriptively using numbers and percentages. The correlation between 2 outcome measures: SPPB and POMA was assessed using Spearman's rank correlation.All the 100 patients had solid tumour malignancies, commonly GI (37%), thoracic (18%), breast (17%), H and N (13%), uro-oncology (11%) and gynecology (4%). The median age was 70 years (range, 60-88). The median BMI was 22.10 (IQR, 19.40-24.77). Among 100 patients, comorbidities were found in most of the patients, most commonly hypertension (35%), diabetes mellitus (20%), heart disease (9%) and other diseases (8%). Out of 100 patients, 15% of them used assistive devices but the remaining 85% of patients did not require any assistive devices. Different outcome measures were also assessed for understanding the patients' risk in different categories. On assessing POMA, most of the patients had a medium risk of fall (49%), followed by high risk (31%) and low risk (14%). On assessing SPPB, most of the patients had low risk (41%), followed by medium risk (31%) and high risk (28%). The aerobic capacity of patients was assessed using 6 MWT (walking capacity) which showed that most of them had a severe reduction in aerobic capacity (37%) followed by moderation reduction (28%), good aerobic capacity (25%) and mild reduction (10%). The treatment required by the patients involved most commonly LL strengthening (71; 30.6%) and aerobic conditioning (67; 28.9%) and the least was brisk walking (4; 1.72%) and UL strengthening (2; 0.86%).</p><p><strong>Conclusion: </strong>Commonly deranged domains included fatig
目的和目标分析老年患者的年龄、性别、体重指数(BMI)、合并症、癌症类型和辅助设备使用情况等各方面因素,并找出短期体能测试(SPPB)和以表现为导向的行动能力评估(POMA)等结果测量之间的相关性:方法:对 60 岁以上的患者进行筛查,并进一步转诊至物理治疗部门。记录简短病史以检索人口统计学数据,如姓名、年龄、性别、身高、体重、体重指数(BMI)、手部优势、诊断、既往检查、合并症(如有)、辅助设备(如有)的使用情况以及既往是否接受过肿瘤治疗。对患者进行了各种结果测量,如 POMA、SPPB、6 分钟步行测试(6 MWT)和疲劳度数字评级。在病例报告单上记录解释结果,并针对患者的缺陷采取适当的干预措施。此外,还要求患者继续进行必要的检查(如有需要),并返回物理治疗手术室。由于这是一项回顾性单终点研究,因此患者无需进行随访:使用 R 软件(4.2.3 版)进行了描述性分析。主要目的是使用数字和百分比对变量进行描述性分析。两个结果指标之间的相关性:所有 100 名患者均为实体瘤恶性肿瘤,常见的有消化系统肿瘤(37%)、胸部肿瘤(18%)、乳腺肿瘤(17%)、甲状腺肿瘤(13%)、泌尿肿瘤(11%)和妇科肿瘤(4%)。年龄中位数为 70 岁(60-88 岁不等)。体重指数中位数为 22.10(IQR,19.40-24.77)。在 100 名患者中,大多数患者都有合并症,最常见的是高血压(35%)、糖尿病(20%)、心脏病(9%)和其他疾病(8%)。在 100 名患者中,15% 的患者使用辅助设备,其余 85% 的患者不需要任何辅助设备。为了解不同类别患者的风险,还对不同的结果指标进行了评估。在评估跌倒风险时,大多数患者的跌倒风险为中度(49%),其次是高风险(31%)和低风险(14%)。在评估 SPPB 时,大多数患者有低风险(41%),其次是中风险(31%)和高风险(28%)。使用 6 MWT(步行能力)对患者的有氧能力进行了评估,结果显示大多数患者的有氧能力严重下降(37%),其次是中度下降(28%)、良好(25%)和轻度下降(10%)。患者需要的治疗最常见的是 LL 强化(71;30.6%)和有氧调节(67;28.9%),最少的是快走(4;1.72%)和 UL 强化(2;0.86%):常见的失常领域包括疲劳(97%)、跌倒风险(80%)、有氧运动能力下降(75%)和合并症(73%)。使用斯皮尔曼等级相关法评估了 SPPB 和 POMA 之间的相关性,相关系数为 0.79,这意味着 SPPB 和 POMA 之间存在很强的正相关性。
{"title":"A physiotherapists perspective of a geriatric clinic in a tertiary oncology centre.","authors":"Ankita Chitre, Akhil Kapoor, Bipinesh Sansar, Anuj Gupta, Praveen Lakshmanamurthy, Somnath Dey, Kunal Vinayak, Ajit Sahoo, Navneet Kaur, Sumaiya Azeem, Dipti Kadu, Akash Anand Shrivastav","doi":"10.3332/ecancer.2024.1774","DOIUrl":"10.3332/ecancer.2024.1774","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims and objectives: &lt;/strong&gt;To analyse various domains amongst the geriatric population such as age, gender, body mass index (BMI), comorbidities, type of cancer and use of assistive devices, and find a correlation between the outcome measures such as short physical performance battery (SPPB) and performance-oriented mobility assessment (POMA).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;Patients above 60 years were screened and further referred to the physiotherapy department. A brief history was recorded to retrieve the demographic data such as name, age, gender, height, weight, BMI, hand dominance, diagnosis, previous investigations are done, comorbidities if any present, use of assistive devices if required and in case any previous oncological treatment has been delivered. Various outcome measures were administered such as POMA, SPPB, 6 minutes walk test (6 MWT) and numerical rating for fatigue. The interpretations were noted on a case report sheet and the appropriate interventions for the deficits were delivered to the patient. Also, the patients were asked to carry on the necessary investigation (if required) and get back to the physiotherapy OPD. No follow-up is required by the patients as this was a retrospective single-endpoint study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results and analysis: &lt;/strong&gt;The descriptive analysis was done by using R software (version 4.2.3). The main objective was to analyse the variables descriptively using numbers and percentages. The correlation between 2 outcome measures: SPPB and POMA was assessed using Spearman's rank correlation.All the 100 patients had solid tumour malignancies, commonly GI (37%), thoracic (18%), breast (17%), H and N (13%), uro-oncology (11%) and gynecology (4%). The median age was 70 years (range, 60-88). The median BMI was 22.10 (IQR, 19.40-24.77). Among 100 patients, comorbidities were found in most of the patients, most commonly hypertension (35%), diabetes mellitus (20%), heart disease (9%) and other diseases (8%). Out of 100 patients, 15% of them used assistive devices but the remaining 85% of patients did not require any assistive devices. Different outcome measures were also assessed for understanding the patients' risk in different categories. On assessing POMA, most of the patients had a medium risk of fall (49%), followed by high risk (31%) and low risk (14%). On assessing SPPB, most of the patients had low risk (41%), followed by medium risk (31%) and high risk (28%). The aerobic capacity of patients was assessed using 6 MWT (walking capacity) which showed that most of them had a severe reduction in aerobic capacity (37%) followed by moderation reduction (28%), good aerobic capacity (25%) and mild reduction (10%). The treatment required by the patients involved most commonly LL strengthening (71; 30.6%) and aerobic conditioning (67; 28.9%) and the least was brisk walking (4; 1.72%) and UL strengthening (2; 0.86%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Commonly deranged domains included fatig","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1774"},"PeriodicalIF":1.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of human papilloma virus infection and risk of cervical intraepithelial neoplasia among female sex workers in Mumbai, India. 印度孟买女性性工作者的人类乳头瘤病毒感染率和宫颈上皮内瘤变风险。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-19 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1772
Vandita Pahwa, Sharmila A Pimple, Gauravi A Mishra, Parishi Majmudar, Sanjay K Biswas, Kedar Deodhar

Introduction: Cervical cancer, mostly caused by human papilloma virus (HPV), has disproportionately high incidence in developing countries. HPV infection being essentially a sexually transmitted infection, high-risk behaviour women with multiple sexual contacts like female sex workers (FSWs) are at higher risk of co-infection with HPV and of developing cervical precancer and cancer.

Objective: This study aimed to determine the prevalence and determinants of HPV infection and cervical intraepithelial neoplasia (CIN) among FSWs in Mumbai, India.

Methods: A cross-sectional study was conducted among 448 FSWs, between the ages of 18-50 years, by collaborating with local non-government organizations working for the health and welfare of FSW communities at sexually transmitted diseases clinics. All FSWs were screened for HPV DNA by hybrid capture II followed by reference diagnosis of colposcopy and/or cervical biopsy.

Results: The prevalence of HPV DNA positivity was 35.5% and CIN was 2.2%. Factors significantly associated with HPV DNA positivity were age group younger than 30 years odds ratio (OR = 2.098, 95% confidence interval (CI) 1.408-3.127), Illiteracy (OR = 2.015, 95% CI 1.305-3.112), being single (OR = 2.409, 95% CI 1.558-3.724), less than 18 years of age at time of initiating work as FSW (OR = 3.718, 95% CI 3.718-2.392), having more than five clients per day (OR = 2.078, 95% CI 1.301-3.318), been working as a FSW for more than 5 years (OR = 2.321, 95% CI 1.455-3.701), not using barrier contraception methods (OR = 5.155, 95% CI 3.395-7.827) and having no exposure to human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) education program (OR = 29.153, 95% CI 15.385-55.240). FSWs with a positive HPV DNA test are substantially more likely to have CIN compared to those with a negative test (OR = 7.6, 95% CI 1.59-36.25).

Conclusion: The prevalence of HPV infection and CIN was high among FSWs. FSWs with a positive HPV DNA test had a seven times higher risk of developing CIN. The persistence of HPV infection is expected to significantly raise the risk of cervical cancer in the future. It is suggested to have an integrated approach towards cervical cancer screening and HIV/AIDS control activities.

导言:宫颈癌主要由人类乳头瘤病毒(HPV)引起,在发展中国家的发病率极高。HPV 感染本质上是一种性传播感染,像女性性工作者(FSWs)这样有多次性接触的高危行为妇女合并感染 HPV 以及罹患宫颈癌前病变和宫颈癌的风险更高:本研究旨在确定印度孟买女性性工作者中 HPV 感染和宫颈上皮内瘤变(CIN)的流行率和决定因素:通过与当地非政府组织合作,在性传播疾病诊所对 448 名年龄在 18-50 岁之间的女性外阴残割者进行了横断面研究。所有女性外阴残割者都接受了混合捕获 II 型人乳头状瘤病毒 DNA 筛查,然后通过阴道镜检查和/或宫颈活检进行参考诊断:结果:HPV DNA 阳性率为 35.5%,CIN 为 2.2%。与 HPV DNA 阳性明显相关的因素有:年龄组小于 30 岁的几率比(OR = 2.098,95% 置信区间 (CI):1.408-3.127)、文盲(OR = 2.015,95% CI:1.305-3.112)、单身(OR = 2.409,95% CI:1.558-3.724)、开始从事家庭主妇工作时年龄小于 18 岁(OR = 3.718,95% CI:3.718-2.392)、有 5 次以上的性生活(OR = 2.098,95% CI:1.408-3.127)。392),每天有超过 5 个客户(OR = 2.078,95% CI 1.301-3.318),从事家庭主妇工作超过 5 年(OR = 2.321,95% CI 1.455-3.701),不使用屏障避孕方法(OR = 5.155,95% CI 3.395-7.827),没有接触过人体免疫缺陷病毒(HIV)/获得性免疫缺陷综合症(AIDS)教育计划(OR = 29.153,95% CI 15.385-55.240)。与检测结果呈阴性的女性同性恋者相比,HPV DNA 检测呈阳性的女性同性恋者患 CIN 的几率要高得多(OR = 7.6,95% CI 1.59-36.25):结论:FSW 中 HPV 感染和 CIN 的发病率很高。结论:HPV DNA 检测呈阳性的女性外阴残割者罹患 CIN 的风险高出七倍。人类乳头瘤病毒感染的持续存在预计将大大增加未来罹患宫颈癌的风险。建议采取综合方法开展宫颈癌筛查和艾滋病毒/艾滋病控制活动。
{"title":"Prevalence of human papilloma virus infection and risk of cervical intraepithelial neoplasia among female sex workers in Mumbai, India.","authors":"Vandita Pahwa, Sharmila A Pimple, Gauravi A Mishra, Parishi Majmudar, Sanjay K Biswas, Kedar Deodhar","doi":"10.3332/ecancer.2024.1772","DOIUrl":"10.3332/ecancer.2024.1772","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer, mostly caused by human papilloma virus (HPV), has disproportionately high incidence in developing countries. HPV infection being essentially a sexually transmitted infection, high-risk behaviour women with multiple sexual contacts like female sex workers (FSWs) are at higher risk of co-infection with HPV and of developing cervical precancer and cancer.</p><p><strong>Objective: </strong>This study aimed to determine the prevalence and determinants of HPV infection and cervical intraepithelial neoplasia (CIN) among FSWs in Mumbai, India.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among 448 FSWs, between the ages of 18-50 years, by collaborating with local non-government organizations working for the health and welfare of FSW communities at sexually transmitted diseases clinics. All FSWs were screened for HPV DNA by hybrid capture II followed by reference diagnosis of colposcopy and/or cervical biopsy.</p><p><strong>Results: </strong>The prevalence of HPV DNA positivity was 35.5% and CIN was 2.2%. Factors significantly associated with HPV DNA positivity were age group younger than 30 years odds ratio (OR = 2.098, 95% confidence interval (CI) 1.408-3.127), Illiteracy (OR = 2.015, 95% CI 1.305-3.112), being single (OR = 2.409, 95% CI 1.558-3.724), less than 18 years of age at time of initiating work as FSW (OR = 3.718, 95% CI 3.718-2.392), having more than five clients per day (OR = 2.078, 95% CI 1.301-3.318), been working as a FSW for more than 5 years (OR = 2.321, 95% CI 1.455-3.701), not using barrier contraception methods (OR = 5.155, 95% CI 3.395-7.827) and having no exposure to human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) education program (OR = 29.153, 95% CI 15.385-55.240). FSWs with a positive HPV DNA test are substantially more likely to have CIN compared to those with a negative test (OR = 7.6, 95% CI 1.59-36.25).</p><p><strong>Conclusion: </strong>The prevalence of HPV infection and CIN was high among FSWs. FSWs with a positive HPV DNA test had a seven times higher risk of developing CIN. The persistence of HPV infection is expected to significantly raise the risk of cervical cancer in the future. It is suggested to have an integrated approach towards cervical cancer screening and HIV/AIDS control activities.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1772"},"PeriodicalIF":1.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study of incidence, mortality and disability adjusted life years (DALYs) for leading cancers in BRICS countries. 金砖五国主要癌症发病率、死亡率和残疾调整寿命年数(DALYs)比较研究。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-19 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1773
Anita Nath, Ruchita Taneja, Yamini Saraswathi Thadi, Gokul Sarveswaran, Prashant Mathur

Background: While cancer stands as a prominent global contributor to mortality, the BRICS countries, which contribute a considerable proportion of the world's economy, also account for a substantial proportion of global cancer-related deaths. The study aims to compile data on the incidence, mortality and disability-adjusted life years (DALYs) of leading cancers in BRICS countries to assess any variations in these parameters.

Methods: Indicators such as the age-standardised incidence rate (ASIR) and age-standardised mortality rate (ASMR) were abstracted from GLOBOCAN 2022. Global Burden of Disease 2019 provided an overview of DALYs. Additionally, 'Cancer Tomorrow' provided projections for future cancer rates up to 2050.

Results: The findings revealed that Russia had the highest ASIR for both sexes. Among males, leading cancer sites included prostate, lung and colorectum, while India stood out with lip and oral cavity cancer as the primary site. Breast cancer dominated among females in all BRICS countries, except China, where lung cancer took precedence. South Africa recorded the highest ASMR for both sexes, with Russia leading among males and South Africa among females. Lung cancer has been the leading cause of death in all countries except India, where breast cancer leads. Trachea, bronchus and lung cancers contributed the most to DALYs, except in India, where breast cancer prevailed. South Africa and India are anticipated to have the highest increase in new cancer cases and deaths in future.

Conclusion: Breast and lung cancers accounted for the highest incidence, mortality and DALYs in females and males, respectively. Although the BRICS countries anticipate sustained economic growth and have viable cancer control plans, it is essential to investigate cancer risk factors and health systems influencing cancer incidence and outcomes.

背景:癌症是导致全球死亡的一个主要因素,而金砖五国在世界经济中占有相当大的比重,它们也占全球癌症相关死亡人数的很大比例。本研究旨在汇编金砖国家主要癌症的发病率、死亡率和残疾调整生命年(DALYs)数据,以评估这些参数的变化情况:年龄标准化发病率(ASIR)和年龄标准化死亡率(ASMR)等指标摘自《2022 年全球疾病负担》。2019 年全球疾病负担》概述了残疾调整生命年。此外,"明日癌症 "提供了到 2050 年的未来癌症发病率预测:结果:研究结果表明,俄罗斯男女的 ASIR 均为最高。男性主要罹患癌症的部位包括前列腺癌、肺癌和结直肠癌,而印度则以唇癌和口腔癌为主。在所有金砖国家中,除中国以肺癌为主外,其他国家的女性均以乳腺癌为主。南非记录的男性和女性 ASMR 都是最高的,俄罗斯在男性中居首位,南非在女性中居首位。除印度外,肺癌一直是所有国家的主要死因,而印度则以乳腺癌居首。气管、支气管和肺癌对残疾调整寿命年数的贡献最大,但印度除外,该国以乳腺癌为主。预计南非和印度未来新增癌症病例和死亡人数的增幅最大:结论:乳腺癌和肺癌分别是女性和男性中发病率、死亡率和残疾调整寿命年数最高的癌症。尽管金砖五国预计经济将持续增长,并制定了可行的癌症控制计划,但仍有必要调查影响癌症发病率和结果的癌症风险因素和卫生系统。
{"title":"A comparative study of incidence, mortality and disability adjusted life years (DALYs) for leading cancers in BRICS countries.","authors":"Anita Nath, Ruchita Taneja, Yamini Saraswathi Thadi, Gokul Sarveswaran, Prashant Mathur","doi":"10.3332/ecancer.2024.1773","DOIUrl":"10.3332/ecancer.2024.1773","url":null,"abstract":"<p><strong>Background: </strong>While cancer stands as a prominent global contributor to mortality, the BRICS countries, which contribute a considerable proportion of the world's economy, also account for a substantial proportion of global cancer-related deaths. The study aims to compile data on the incidence, mortality and disability-adjusted life years (DALYs) of leading cancers in BRICS countries to assess any variations in these parameters.</p><p><strong>Methods: </strong>Indicators such as the age-standardised incidence rate (ASIR) and age-standardised mortality rate (ASMR) were abstracted from GLOBOCAN 2022. Global Burden of Disease 2019 provided an overview of DALYs. Additionally, 'Cancer Tomorrow' provided projections for future cancer rates up to 2050.</p><p><strong>Results: </strong>The findings revealed that Russia had the highest ASIR for both sexes. Among males, leading cancer sites included prostate, lung and colorectum, while India stood out with lip and oral cavity cancer as the primary site. Breast cancer dominated among females in all BRICS countries, except China, where lung cancer took precedence. South Africa recorded the highest ASMR for both sexes, with Russia leading among males and South Africa among females. Lung cancer has been the leading cause of death in all countries except India, where breast cancer leads. Trachea, bronchus and lung cancers contributed the most to DALYs, except in India, where breast cancer prevailed. South Africa and India are anticipated to have the highest increase in new cancer cases and deaths in future.</p><p><strong>Conclusion: </strong>Breast and lung cancers accounted for the highest incidence, mortality and DALYs in females and males, respectively. Although the BRICS countries anticipate sustained economic growth and have viable cancer control plans, it is essential to investigate cancer risk factors and health systems influencing cancer incidence and outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1773"},"PeriodicalIF":1.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review. 微卫星稳定型结直肠癌的肝转移和免疫疗法耐药性。文献综述。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-18 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1771
Marcelo Porfirio Sunagua Aruquipa, Mauro S Donadio, Renata D Peixoto

Background: Microsatellite stable (MSS) metastatic colorectal cancer (CRC) remains predominantly managed with chemotherapy. The use of immunotherapy, whether alone or in combination with other systemic or local treatments, displays limited success, especially in the context of active liver metastases (LM). The mechanisms responsible for this resistance are not fully understood.

Methods: We conducted a comprehensive search across electronic databases such as Medline, PubMed, Google Scholar and ScienceDirect. This search targeted translational studies evaluating the liver tumour immune microenvironment and immune tolerance mechanisms in CRC with LM and prospective studies that assessed immunotherapy either as a standalone treatment or in combination with other systemic or local therapies for patients diagnosed with MSS CRC. Our primary objectives included elucidating the mechanisms of resistance originating from LM in a non-systematic literature review and presenting a summary of the outcomes observed in prospective trials utilising immune checkpoint inhibitors (ICIs), with a focus on the presence of LM.

Findings: There were 16 prospective trials evaluating immunotherapy for metastatic CRC comprising 1,713 patients. Response rates to immunotherapy inpatients with colorectal liver metastases (CRLM) varied from 0% to 23%. Overall, reduced or null responses to immunotherapy in the presence of liver metastasis in comparison to patients without liver involvement were observed.

Conclusion: Studies consistently show the resistance derived from classical ICI, both alone and in combination with other systemic treatments in patients with CRLM. The design of upcoming trials using immunotherapy should consider LM as a stratification factor or contemplate excluding patients with liver involvement.

背景:微卫星稳定型(MSS)转移性结直肠癌(CRC)仍以化疗为主。免疫疗法的使用,无论是单独使用还是与其他全身或局部治疗相结合,都显示出有限的成功率,尤其是在肝转移(LM)活跃的情况下。造成这种耐药性的机制尚未完全明了:我们对 Medline、PubMed、Google Scholar 和 ScienceDirect 等电子数据库进行了全面检索。我们在 Medline、PubMed、Google Scholar 和 ScienceDirect 等电子数据库中进行了全面搜索,目标是评估肝肿瘤免疫微环境和肝癌免疫耐受机制的转化研究,以及评估免疫疗法作为一种独立疗法或与其他系统或局部疗法联合用于确诊为 MSS CRC 患者的前瞻性研究。我们的主要目标包括在非系统性文献综述中阐明源自LM的耐药机制,并对使用免疫检查点抑制剂(ICIs)的前瞻性试验中观察到的结果进行总结,重点关注LM的存在:共有16项前瞻性试验对转移性 CRC 的免疫疗法进行了评估,其中包括1713名患者。结直肠肝转移(CRLM)患者对免疫疗法的应答率从0%到23%不等。总体而言,与没有肝脏受累的患者相比,存在肝转移的患者对免疫疗法的反应减少或无效:研究一致表明,CRLM 患者在单独使用或与其他系统治疗联合使用经典 ICI 时会产生抗药性。在设计即将开展的免疫疗法试验时,应将肝转移作为分层因素,或考虑排除肝脏受累的患者。
{"title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review.","authors":"Marcelo Porfirio Sunagua Aruquipa, Mauro S Donadio, Renata D Peixoto","doi":"10.3332/ecancer.2024.1771","DOIUrl":"10.3332/ecancer.2024.1771","url":null,"abstract":"<p><strong>Background: </strong>Microsatellite stable (MSS) metastatic colorectal cancer (CRC) remains predominantly managed with chemotherapy. The use of immunotherapy, whether alone or in combination with other systemic or local treatments, displays limited success, especially in the context of active liver metastases (LM). The mechanisms responsible for this resistance are not fully understood.</p><p><strong>Methods: </strong>We conducted a comprehensive search across electronic databases such as Medline, PubMed, Google Scholar and ScienceDirect. This search targeted translational studies evaluating the liver tumour immune microenvironment and immune tolerance mechanisms in CRC with LM and prospective studies that assessed immunotherapy either as a standalone treatment or in combination with other systemic or local therapies for patients diagnosed with MSS CRC. Our primary objectives included elucidating the mechanisms of resistance originating from LM in a non-systematic literature review and presenting a summary of the outcomes observed in prospective trials utilising immune checkpoint inhibitors (ICIs), with a focus on the presence of LM.</p><p><strong>Findings: </strong>There were 16 prospective trials evaluating immunotherapy for metastatic CRC comprising 1,713 patients. Response rates to immunotherapy inpatients with colorectal liver metastases (CRLM) varied from 0% to 23%. Overall, reduced or null responses to immunotherapy in the presence of liver metastasis in comparison to patients without liver involvement were observed.</p><p><strong>Conclusion: </strong>Studies consistently show the resistance derived from classical ICI, both alone and in combination with other systemic treatments in patients with CRLM. The design of upcoming trials using immunotherapy should consider LM as a stratification factor or contemplate excluding patients with liver involvement.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1771"},"PeriodicalIF":1.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced-technique radiation therapy for nasopharyngeal carcinoma in a low resource setting: a review of treatment-related quality of life. 在资源匮乏的环境中采用先进技术放射治疗鼻咽癌:与治疗相关的生活质量回顾。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-18 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1770
Godwin Uwagba, Adedayo Joseph, Muhammed Habeebu, Eben Aje, Aishat Oladipo, Olufunmilayo Fagbemide, Precious Akowe, Azeezat Ajose, Adebayo Abe, Samuel Adeneye, Ibrahim Elhamamsi, Abdallah Kotkat, Nusirat Adedewe, Inioluwa Ariyo, Wonuola Adetugbogbo, Francis Durosinmi-Etti

Background: Nasopharyngeal carcinoma (NPC) is a rare but significant public health concern, especially in Africa, with a rising global incidence. This study aimed to investigate the pattern of presentation, treatment outcomes and impact on health-related quality of life (HRQOL) of NPC patients at a tertiary institution in Lagos, Nigeria.

Methodology: A retrospective review of all nasopharyngeal cancer patients (n = 125) treated at a tertiary centre in Lagos, Nigeria, from May 2019 to 2022 was done. The European Organisation for Research and Treatment of Cancer (EORTC) H&N 35 questionnaire was used to assess HRQOL at 1-year post treatment and the data were analysed using a statistical package for the social sciences v26.0.

Results: Among 125 patients, the mean age was 46.21 ± 17.82 years with 76% male. Comorbidities were reported in 34 patients (27.2%), smoking history in 18 patients (14.4%) and 50 patients (40%) reported alcohol consumption. Environmental risk factors were identified in six patients (4.8%). The most prevalent histology was squamous cell carcinoma (92.8%), and stage IV was the most common stage (42.4%). Chemoradiation was the primary treatment (63.2%), with intensity-modulated radiotherapy being the most utilised approach (51.2%). Among 125 patients, 51 completed the EORTC questionnaire. Weight loss, sticky saliva, dry mouth, difficulties in swallowing and problems with the sense of taste and smell were the most severe symptoms reported by patients. In the follow-up, 79.2% of patients were reached (50.4% alive, 28.8% deceased). Mortality was significantly associated with age >65 years, weight loss at presentation and consumption of grilled/smoked food.

Conclusion: The study highlights key aspects of NPC in our region including the predominance in males, advanced disease stage at presentation and persistent symptoms post-treatment. Our findings point to the need for targeted initiatives to improve early detection and quality of life for nasopharyngeal patients in the country.

背景:鼻咽癌(NPC)是一种罕见的公共卫生问题,尤其是在非洲,全球发病率不断上升。本研究旨在调查尼日利亚拉各斯一家三级医疗机构中鼻咽癌患者的发病模式、治疗效果以及对健康相关生活质量(HRQOL)的影响:对2019年5月至2022年期间在尼日利亚拉各斯一家三级医院接受治疗的所有鼻咽癌患者(n = 125)进行回顾性研究。采用欧洲癌症研究和治疗组织(EORTC)H&N 35问卷评估治疗后1年的HRQOL,并使用社会科学统计软件包v26.0对数据进行分析:在125名患者中,平均年龄为(46.21 ± 17.82)岁,男性占76%。34名患者(27.2%)有合并症,18名患者(14.4%)有吸烟史,50名患者(40%)有饮酒史。6名患者(4.8%)存在环境风险因素。最常见的组织学类型是鳞状细胞癌(92.8%),IV期是最常见的分期(42.4%)。化疗是主要的治疗方法(63.2%),而强度调节放疗是最常用的方法(51.2%)。125 名患者中有 51 人填写了 EORTC 问卷。体重减轻、唾液粘稠、口干、吞咽困难以及味觉和嗅觉问题是患者报告的最严重症状。在随访中,79.2%的患者(50.4%存活,28.8%死亡)接受了治疗。死亡率与年龄大于 65 岁、发病时体重减轻和食用烧烤/熏烤食物有明显关系:这项研究强调了本地区鼻咽癌的主要特征,包括男性居多、发病时处于晚期以及治疗后症状持续存在。我们的研究结果表明,有必要采取有针对性的措施,以提高早期发现率和鼻咽癌患者的生活质量。
{"title":"Advanced-technique radiation therapy for nasopharyngeal carcinoma in a low resource setting: a review of treatment-related quality of life.","authors":"Godwin Uwagba, Adedayo Joseph, Muhammed Habeebu, Eben Aje, Aishat Oladipo, Olufunmilayo Fagbemide, Precious Akowe, Azeezat Ajose, Adebayo Abe, Samuel Adeneye, Ibrahim Elhamamsi, Abdallah Kotkat, Nusirat Adedewe, Inioluwa Ariyo, Wonuola Adetugbogbo, Francis Durosinmi-Etti","doi":"10.3332/ecancer.2024.1770","DOIUrl":"10.3332/ecancer.2024.1770","url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a rare but significant public health concern, especially in Africa, with a rising global incidence. This study aimed to investigate the pattern of presentation, treatment outcomes and impact on health-related quality of life (HRQOL) of NPC patients at a tertiary institution in Lagos, Nigeria.</p><p><strong>Methodology: </strong>A retrospective review of all nasopharyngeal cancer patients (<i>n</i> = 125) treated at a tertiary centre in Lagos, Nigeria, from May 2019 to 2022 was done. The European Organisation for Research and Treatment of Cancer (EORTC) H&N 35 questionnaire was used to assess HRQOL at 1-year post treatment and the data were analysed using a statistical package for the social sciences v26.0.</p><p><strong>Results: </strong>Among 125 patients, the mean age was 46.21 ± 17.82 years with 76% male. Comorbidities were reported in 34 patients (27.2%), smoking history in 18 patients (14.4%) and 50 patients (40%) reported alcohol consumption. Environmental risk factors were identified in six patients (4.8%). The most prevalent histology was squamous cell carcinoma (92.8%), and stage IV was the most common stage (42.4%). Chemoradiation was the primary treatment (63.2%), with intensity-modulated radiotherapy being the most utilised approach (51.2%). Among 125 patients, 51 completed the EORTC questionnaire. Weight loss, sticky saliva, dry mouth, difficulties in swallowing and problems with the sense of taste and smell were the most severe symptoms reported by patients. In the follow-up, 79.2% of patients were reached (50.4% alive, 28.8% deceased). Mortality was significantly associated with age >65 years, weight loss at presentation and consumption of grilled/smoked food.</p><p><strong>Conclusion: </strong>The study highlights key aspects of NPC in our region including the predominance in males, advanced disease stage at presentation and persistent symptoms post-treatment. Our findings point to the need for targeted initiatives to improve early detection and quality of life for nasopharyngeal patients in the country.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1770"},"PeriodicalIF":1.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome. 性索卵巢肿瘤 10 年间的临床病理特征和预后回顾分析。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-16 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1769
Mona Naman Shah, Vinotha Thomas, Anjana Joel, Reka Karuppusami, Dhanya Susan Thomas, Ajit Sebastian, Anitha Thomas, Rachel Chandy, Abraham Peedicayil

Objectives: To retrospectively describe the clinicopathological profile and treatment outcome of sex cord ovarian tumours (SCOTs), from a single institution.

Methods: Patients who operated for SCOT between January 2011 and December 2020 were identified from the institution's discharge summaries. Treatment details and oncologic outcomes were analyzed using descriptive statistics, SPSS statistics version 21. Progression-free survival and overall survival were plotted using the Kaplan-Meier method.

Results: Over 10 years, 120 patients underwent surgery with 73 (61%) malignant SCOTs. Eight (6.6%) were referred with recurrence. Granulosa cell histology (61/73, 83.5%) and federation of gynaecology and obstetrics (FIGO) stage I disease (57/65, 78.62%) were predominant. Three (3/26,11.53%) had lymph node involvement. Adjuvant chemotherapy was advised in 53.4% (39/73).Over a median period of 47 months (1-130 months), eleven (15.06%) patients recurred (5-year recurrence rate: 9.58%) and 6 died (5-year survival rate: 89.04%).Among 65 patients with upfront disease, 9 (13.8%) recurred over a median period of 46 months (1-65 months) with 4 disease-related deaths. On univariate analysis, incomplete cytoreduction hazard ratios (HR 58.391, 95% CI 5.042-674.854), advanced FIGO stage (HR 15.931, 3.74-67.89) and nongranulosa histology was associated with recurrence. On multivariate analysis, advanced FIGO stage (HR 20.099, 95% CI 3.75-107.711) and non granulosa histology (HR 31.35, 95% 2.801-350.897 ) remained significant. Lymphadenectomy and adjuvant chemotherapy did not prevent recurrence.

目的回顾性描述一家医疗机构中性索卵巢肿瘤(SCOT)的临床病理特征和治疗结果:方法:从该机构的出院摘要中找出 2011 年 1 月至 2020 年 12 月间接受性索卵巢肿瘤手术的患者。采用描述性统计和 SPSS 统计 21 版分析治疗细节和肿瘤结果。无进展生存期和总生存期采用 Kaplan-Meier 法绘制:10年间,120名患者接受了手术,其中73例(61%)为恶性SCOT。8例(6.6%)因复发而转诊。以颗粒细胞组织学(61/73,83.5%)和妇产科联盟(FIGO)I期疾病(57/65,78.62%)为主。3例(3/26,11.53%)淋巴结受累。在中位 47 个月(1-130 个月)的时间里,11 例(15.06%)患者复发(5 年复发率:9.58%),6 例死亡(5 年生存率:89.04%)。在 65 例前期疾病患者中,9 例(13.8%)在中位 46 个月(1-65 个月)的时间里复发,4 例死亡。单变量分析显示,不完全细胞减灭危险比(HR 58.391,95% CI 5.042-674.854)、晚期 FIGO 分期(HR 15.931,3.74-67.89)和非肉芽组织学与复发有关。在多变量分析中,晚期 FIGO 分期(HR 20.099,95% CI 3.75-107.711)和非颗粒组织学(HR 31.35,95% 2.801-350.897)仍具有显著性。淋巴腺切除术和辅助化疗并不能预防复发。
{"title":"Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome.","authors":"Mona Naman Shah, Vinotha Thomas, Anjana Joel, Reka Karuppusami, Dhanya Susan Thomas, Ajit Sebastian, Anitha Thomas, Rachel Chandy, Abraham Peedicayil","doi":"10.3332/ecancer.2024.1769","DOIUrl":"10.3332/ecancer.2024.1769","url":null,"abstract":"<p><strong>Objectives: </strong>To retrospectively describe the clinicopathological profile and treatment outcome of sex cord ovarian tumours (SCOTs), from a single institution.</p><p><strong>Methods: </strong>Patients who operated for SCOT between January 2011 and December 2020 were identified from the institution's discharge summaries. Treatment details and oncologic outcomes were analyzed using descriptive statistics, SPSS statistics version 21. Progression-free survival and overall survival were plotted using the Kaplan-Meier method.</p><p><strong>Results: </strong>Over 10 years, 120 patients underwent surgery with 73 (61%) malignant SCOTs. Eight (6.6%) were referred with recurrence. Granulosa cell histology (61/73, 83.5%) and federation of gynaecology and obstetrics (FIGO) stage I disease (57/65, 78.62%) were predominant. Three (3/26,11.53%) had lymph node involvement. Adjuvant chemotherapy was advised in 53.4% (39/73).Over a median period of 47 months (1-130 months), eleven (15.06%) patients recurred (5-year recurrence rate: 9.58%) and 6 died (5-year survival rate: 89.04%).Among 65 patients with upfront disease, 9 (13.8%) recurred over a median period of 46 months (1-65 months) with 4 disease-related deaths. On univariate analysis, incomplete cytoreduction hazard ratios (HR 58.391, 95% CI 5.042-674.854), advanced FIGO stage (HR 15.931, 3.74-67.89) and nongranulosa histology was associated with recurrence. On multivariate analysis, advanced FIGO stage (HR 20.099, 95% CI 3.75-107.711) and non granulosa histology (HR 31.35, 95% 2.801-350.897 ) remained significant. Lymphadenectomy and adjuvant chemotherapy did not prevent recurrence.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1769"},"PeriodicalIF":1.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing sexual health in oncology: perspectives and challenges for better care at a national level. 解决肿瘤学中的性健康问题:在国家层面改善护理的观点和挑战。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1765
Natalia Camejo, Camila Montenegro, Dahiana Amarillo, Cecilia Castillo, Gabriel Krygier

Introduction: The emotional impacts of oncological treatments can negatively affect sexual health and intimate relationships. Advances in cancer management have extended patient survival, underscoring the importance of addressing sexual health post-diagnosis.

Objectives: To explore physicians' practices regarding the approach to sexual health during oncological consultations; identifying barriers to addressing sexuality and assessing the need for sexual health training.

Methods: An observational, cross-sectional study that assessed the management of sexual health by physicians involved in oncological treatment, using an anonymous questionnaire distributed via SurveyMonkey.

Results: Of 133 physicians surveyed, 31.6% never or rarely address sexual health. Only 10.5% feel frequently prepared on this topic, while 24.8% almost never have the appropriate tools to address it. 97.7% of oncologists and 92.9% of otolaryngologists (ENTs) recognize the need for sexual health training. Sexual health was more frequently discussed among patients diagnosed with prostate, cervical and breast cancer, and less so among those with ENT, bladder and colorectal tumours. The approach was more frequent among patients treated with curative intent (77.4%) than those with palliative intent (5%). The main barriers identified were lack of training (46%), lack of time (39.8%) and patient discomfort (34.6%).

Conclusion: The majority of professionals dealing with oncological patients do not address their sexual health, with the lack of training, lack of time and patient discomfort being the main barriers identified. However, 92% indicate a need for sexual health training, which could contribute to early intervention, strategy establishment and timely referral to specialists in the field.

导言肿瘤治疗带来的情绪影响会对性健康和亲密关系产生负面影响。癌症治疗的进步延长了患者的生存期,这也凸显了在诊断后解决性健康问题的重要性:目的:探讨医生在肿瘤诊疗过程中处理性健康问题的做法;确定处理性问题的障碍,并评估性健康培训的需求:方法:一项观察性横断面研究,通过 SurveyMonkey 发放匿名问卷,评估参与肿瘤治疗的医生对性健康的管理:结果:在接受调查的 133 名医生中,31.6% 的医生从未或很少处理性健康问题。只有 10.5%的医生认为自己经常就这一主题做好准备,24.8%的医生几乎从未掌握过解决这一问题的适当工具。97.7%的肿瘤科医生和92.9%的耳鼻喉科医生认识到性健康培训的必要性。前列腺癌、宫颈癌和乳腺癌患者更经常讨论性健康问题,而耳鼻喉科、膀胱癌和结肠直肠癌患者则较少讨论。以治愈为目的的患者(77.4%)比以姑息为目的的患者(5%)更经常采用这种方法。发现的主要障碍是缺乏培训(46%)、缺乏时间(39.8%)和病人不适(34.6%):结论:与肿瘤患者打交道的大多数专业人员都没有关注过他们的性健康问题,缺乏培训、没有时间和患者不适是主要障碍。然而,92%的人表示需要性健康培训,这有助于早期干预、制定策略和及时转诊给该领域的专家。
{"title":"Addressing sexual health in oncology: perspectives and challenges for better care at a national level.","authors":"Natalia Camejo, Camila Montenegro, Dahiana Amarillo, Cecilia Castillo, Gabriel Krygier","doi":"10.3332/ecancer.2024.1765","DOIUrl":"10.3332/ecancer.2024.1765","url":null,"abstract":"<p><strong>Introduction: </strong>The emotional impacts of oncological treatments can negatively affect sexual health and intimate relationships. Advances in cancer management have extended patient survival, underscoring the importance of addressing sexual health post-diagnosis.</p><p><strong>Objectives: </strong>To explore physicians' practices regarding the approach to sexual health during oncological consultations; identifying barriers to addressing sexuality and assessing the need for sexual health training.</p><p><strong>Methods: </strong>An observational, cross-sectional study that assessed the management of sexual health by physicians involved in oncological treatment, using an anonymous questionnaire distributed via SurveyMonkey.</p><p><strong>Results: </strong>Of 133 physicians surveyed, 31.6% never or rarely address sexual health. Only 10.5% feel frequently prepared on this topic, while 24.8% almost never have the appropriate tools to address it. 97.7% of oncologists and 92.9% of otolaryngologists (ENTs) recognize the need for sexual health training. Sexual health was more frequently discussed among patients diagnosed with prostate, cervical and breast cancer, and less so among those with ENT, bladder and colorectal tumours. The approach was more frequent among patients treated with curative intent (77.4%) than those with palliative intent (5%). The main barriers identified were lack of training (46%), lack of time (39.8%) and patient discomfort (34.6%).</p><p><strong>Conclusion: </strong>The majority of professionals dealing with oncological patients do not address their sexual health, with the lack of training, lack of time and patient discomfort being the main barriers identified. However, 92% indicate a need for sexual health training, which could contribute to early intervention, strategy establishment and timely referral to specialists in the field.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1765"},"PeriodicalIF":1.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familiar cylindromatosis in a Colombian family caused by a mutation in CYLD. 由 CYLD 基因突变引起的哥伦比亚一个家族的熟悉圆柱状瘤病。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1768
Lisa Ximena Rodríguez Rojas, Diana Vasquez-Forero, Juan José Albán, Liliana Doza, Sandra Murillo, Jorge Andrés Olave-Rodriguez, José Nastasi

Introduction: The CYLD cutaneous syndrome is characterised by the appearance of multiple skin tumours, including cylindromas, spiradenomas, trichoepitheliomas and basal cell adenomas of the salivary gland and less frequently pulmonary cylindromas. The lesions appear in the second decade of life, typically present as single lesions, located mainly on the face and head and progressively increase in number, potentially affecting the torso, groin and axillae. Although lesions can affect both men and women, a higher frequency of affected women has been described.

Case presentation: CYLD cutaneous syndrome is caused by pathogenic variants in the CYLD gene, following an autosomal dominant inheritance pattern. We present the first Colombian case of a family affected by CYLD cutaneous syndrome, spanning three generations and characterised by early onset of skin lesions. This syndrome was molecularly confirmed by next-generation sequencing (NGS), reveling a heterozygous frameshift variant in the CYLD gene, specifically the type NM_015247.2 c.2291_2295delAACTA p.Lys764Ilefs*2, which was subsequently confirmed by Sanger sequencing.

Conclusion: Understanding the complex interplay of genetic, epigenetic and environmental factors in the malignant transformation of cylindroma to squamous eccrine ductal carcinoma is crucial for developing targeted therapies and improving patient outcomes.

Key messages: The CYLD cutaneous syndrome in a Colombian family.

导言:CYLD皮肤综合征的特征是出现多种皮肤肿瘤,包括唾液腺的圆柱瘤、螺旋腺瘤、三上皮瘤和基底细胞腺瘤,以及较少见的肺圆柱瘤。病变出现在患者出生后的第二个十年,通常为单发病变,主要位于面部和头部,病变数目逐渐增多,有可能累及躯干、腹股沟和腋窝。虽然男女均可发病,但女性发病率较高:病例介绍:CYLD 皮肤综合征是由 CYLD 基因的致病变异引起的,呈常染色体显性遗传模式。我们在哥伦比亚首次发现了一个患有 CYLD 皮肤综合征的家族病例,该家族三代人都患有该病,其特点是皮肤病变发病较早。该综合征通过下一代测序(NGS)得到分子证实,揭示了 CYLD 基因中的一个杂合框移变异,特别是 NM_015247.2 c.2291_2295delAACTA p.Lys764Ilefs*2 型,该变异随后通过桑格测序得到证实:结论:了解遗传、表观遗传和环境因素在圆柱瘤向鳞状棘皮导管癌恶性转化过程中的复杂相互作用,对于开发靶向疗法和改善患者预后至关重要:哥伦比亚一个家族的CYLD皮肤综合征。
{"title":"Familiar cylindromatosis in a Colombian family caused by a mutation in CYLD.","authors":"Lisa Ximena Rodríguez Rojas, Diana Vasquez-Forero, Juan José Albán, Liliana Doza, Sandra Murillo, Jorge Andrés Olave-Rodriguez, José Nastasi","doi":"10.3332/ecancer.2024.1768","DOIUrl":"10.3332/ecancer.2024.1768","url":null,"abstract":"<p><strong>Introduction: </strong>The CYLD cutaneous syndrome is characterised by the appearance of multiple skin tumours, including cylindromas, spiradenomas, trichoepitheliomas and basal cell adenomas of the salivary gland and less frequently pulmonary cylindromas. The lesions appear in the second decade of life, typically present as single lesions, located mainly on the face and head and progressively increase in number, potentially affecting the torso, groin and axillae. Although lesions can affect both men and women, a higher frequency of affected women has been described.</p><p><strong>Case presentation: </strong>CYLD cutaneous syndrome is caused by pathogenic variants in the CYLD gene, following an autosomal dominant inheritance pattern. We present the first Colombian case of a family affected by CYLD cutaneous syndrome, spanning three generations and characterised by early onset of skin lesions. This syndrome was molecularly confirmed by next-generation sequencing (NGS), reveling a heterozygous frameshift variant in the CYLD gene, specifically the type NM_015247.2 c.2291_2295delAACTA p.Lys764Ilefs*2, which was subsequently confirmed by Sanger sequencing.</p><p><strong>Conclusion: </strong>Understanding the complex interplay of genetic, epigenetic and environmental factors in the malignant transformation of cylindroma to squamous eccrine ductal carcinoma is crucial for developing targeted therapies and improving patient outcomes.</p><p><strong>Key messages: </strong>The CYLD cutaneous syndrome in a Colombian family.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1768"},"PeriodicalIF":1.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemoglobin level and survival in cervical cancer with chemoradiotherapy at high altitude, 2020-2022. 2020-2022 年在高海拔地区接受化疗放疗的宫颈癌患者的血红蛋白水平和生存率。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1767
José Fernando Robles Díaz

Background: The purpose of this retrospective study was to determine the prognosis of altitude and pre-treatment hemoglobin (Hb) levels with progression-free survival (PFS) among women from the jungle and Andean regions of Peru with cervical cancer (CC) receiving weekly cisplatin and concurrent radiotherapy followed by brachytherapy or teletherapy boost.

Methods: Patients with advanced clinical stage II-IVA CC were grouped according to Hb level (≥ 12.0, 11.9-10.0, 9.9-9.0 and ≤ 8.9 g/dL). Outcome measures were PFS, overall survival and local PFS.

Findings: Between 1/2020 and 12/2022, 159 patients contributed demographic, clinical, pre-treatment Hb and outcome data with a median follow-up of 38 months. Kaplan-Meier estimates for survivals according to pre-treatment Hb level were significant when compared to a level of ≤8.9 g/dL, while estimates with altitude did not show statistical significance. Cox regression analysis of PFS demonstrated that pre-treatment Hb levels ≤8.9 g/dL (p = 0.000) were a significant factor. Age (p = 0.023), stage (p = 0.000), tumour size (p = 0.006) and treatment duration (p = 0.000) were also significant in the regression model.

Interpretation: There is no difference between altitude and survival, but the difference in pre-treatment Hb level was a prognostic indicator of survival, with a Hb level of ≤8.9 g/dL being the worst prognosis.

研究背景这项回顾性研究的目的是确定秘鲁丛林和安第斯地区妇女宫颈癌(CC)患者在接受每周顺铂和同期放疗后接受近距离放疗或远距离放疗的无进展生存期(PFS)与海拔高度和治疗前血红蛋白(Hb)水平的预后关系:根据血红蛋白水平(≥ 12.0、11.9-10.0、9.9-9.0 和≤ 8.9 g/dL)对临床 II-IVA 期晚期宫颈癌患者进行分组。结果指标为PFS、总生存期和局部PFS:在 2020 年 1 月 1 日至 2022 年 12 月 12 日期间,159 名患者提供了人口统计学、临床、治疗前 Hb 和结果数据,中位随访时间为 38 个月。与治疗前 Hb 水平≤8.9 g/dL 相比,根据治疗前 Hb 水平得出的 Kaplan-Meier 存活率估计值具有显著性,而根据海拔高度得出的估计值则没有统计学意义。PFS的Cox回归分析表明,治疗前Hb水平≤8.9 g/dL(p = 0.000)是一个重要因素。年龄(p = 0.023)、分期(p = 0.000)、肿瘤大小(p = 0.006)和治疗时间(p = 0.000)在回归模型中也具有显著性:海拔高度与生存率之间没有差异,但治疗前 Hb 水平的差异是生存率的预后指标,Hb 水平≤8.9 g/dL 预后最差。
{"title":"Hemoglobin level and survival in cervical cancer with chemoradiotherapy at high altitude, 2020-2022.","authors":"José Fernando Robles Díaz","doi":"10.3332/ecancer.2024.1767","DOIUrl":"10.3332/ecancer.2024.1767","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this retrospective study was to determine the prognosis of altitude and pre-treatment hemoglobin (Hb) levels with progression-free survival (PFS) among women from the jungle and Andean regions of Peru with cervical cancer (CC) receiving weekly cisplatin and concurrent radiotherapy followed by brachytherapy or teletherapy boost.</p><p><strong>Methods: </strong>Patients with advanced clinical stage II-IVA CC were grouped according to Hb level (≥ 12.0, 11.9-10.0, 9.9-9.0 and ≤ 8.9 g/dL). Outcome measures were PFS, overall survival and local PFS.</p><p><strong>Findings: </strong>Between 1/2020 and 12/2022, 159 patients contributed demographic, clinical, pre-treatment Hb and outcome data with a median follow-up of 38 months. Kaplan-Meier estimates for survivals according to pre-treatment Hb level were significant when compared to a level of ≤8.9 g/dL, while estimates with altitude did not show statistical significance. Cox regression analysis of PFS demonstrated that pre-treatment Hb levels ≤8.9 g/dL (<i>p</i> = 0.000) were a significant factor. Age (<i>p</i> = 0.023), stage (<i>p</i> = 0.000), tumour size (<i>p</i> = 0.006) and treatment duration (<i>p</i> = 0.000) were also significant in the regression model.</p><p><strong>Interpretation: </strong>There is no difference between altitude and survival, but the difference in pre-treatment Hb level was a prognostic indicator of survival, with a Hb level of ≤8.9 g/dL being the worst prognosis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1767"},"PeriodicalIF":1.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ecancermedicalscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1